StockTipsArenaBeta

BUY Dr. Reddy's Laboratories Limited — Prakash Gaba

BUYDr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories share price target & all analyst calls

byPrakash GabaHorizon: NA (inferred Swing (≤2wk))11 Aug 2026via CNBC Awaaz.

Entry₹1,201Inferred
Target₹1,220
Total upside +1.58% (call closed)
Stop loss₹1,195-0.50% risk
Exit₹1,19512 Aug 2026, 9:25 am
Stop-loss hit-0.50%
Follow Prakash Gaba for new calls(30% target hit, 299 closed calls)Get alertsWatch DRREDDY for new buy/sell callsGet alertsSee 4 active Swing calls on DRREDDYSee 149 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 12 Aug 2026
4 supporting2 neutral1 opposing
Supports the BUY call (4)

1 advisor has an active short-term BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·11 Aug · today

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·4 Aug · 1w ago

Dr. Reddy's Laboratories has received U.S. FDA approval for its rituximab biosimilar. Fresenius Kabi will exclusively commercialize the product in the United States. This approval strengthens Dr. Redd

BSE · Company Update·1 Aug · 1w ago

(opens in new tab)

Dr Reddy's Laboratories Ltd received approval for its gonorrhea drug from Thailand, following a US nod, as reported by Business Standard.

BSE · Company Update·28 Jul · 2w ago

(opens in new tab)
Neutral / worth noting (2)

Dr Reddy's ends distribution deal with Novartis India after ownership change

NewsCnbc-Tv18·7 Aug · 4d ago

(opens in new tab)

Dr Reddy’s Srikakulam facility in Andhra Pradesh gets UFDA Form 483 with 3 observations

NewsCnbc-Tv18·30 Jul · 2w ago

(opens in new tab)
Weighs against the BUY call (1)

1 advisor has an active short-term SELL call on this stock

Advisor consensus · adjacent horizon·9 Jul · 1mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Reddy's Laboratories

All analyst calls on Dr. Reddy's Laboratories

More from Prakash Gaba

Every call and its outcome